Go Pro
LON:BVXP

Bioventix Interim Earnings Report

Bioventix logo
GBX 1,500 0.00 (0.00%)
As of 12:03 PM Eastern

Bioventix EPS Results

Actual EPS
GBX 69.38
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Bioventix Revenue Results

Actual Revenue
$6.16 billion
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Bioventix Announcement Details

Quarter
Interim
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Bioventix Earnings Headlines

Peter Harrison Spends UK£39k On Bioventix Stock
He bet half his $9 billion on ONE stock
One of the most successful fund managers of the past 50 years put more than $4.5 billion - over half his fund - into a single, little-known company. His firm then bought more shares for 61 straight trading days, and the former CEO of Google soon struck a nine-figure partnership with the same company. This company controls nearly a million acres of scarce, irreplaceable minerals now protected by a White House executive order signed January 14, 2026. It has already outperformed Apple, Amazon, and the S-P 500 combined - and Whitney Tilson believes the biggest gains are still ahead.tc pixel
See More Bioventix Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Bioventix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bioventix and other key companies, straight to your email.

About Bioventix

Bioventix (LON:BVXP) creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; and Pyrene (HOP-G) ELISA kit to monitor human exposure to industrial pollutants. It also provides contract SMAs and recombinant services. Bioventix PLC was incorporated in 2003 and is based in Farnham, United Kingdom.

View Bioventix Profile